ASH First Look: CAR-T Therapies Against BCMA, CD19 And More

CAR-T therapies from Janssen, Celgene and others will get a lot of attention at the annual hematology meeting, including candidates with novel constructs and targets. 

Binocular viewer_1200X675
BCMA CAR-T still is a hot topic, but novel therapies advance at ASH.

More from Clinical Trials

More from R&D